Key facts

Active Substance
Elacytarabine
Therapeutic area
Oncology
Decision number
P/0043/2012
PIP number
EMEA-001121-PIP01-10
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
Treatment of acute myeloid leukaemia
Route(s) of administration
Intravenous use
Contact for public enquiries

Clavis Pharma ASA 

Norway 
mail@clavispharma.com 
+47 24110850 
+47 24110951

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page